公开(公告)号：US11738009B2

公开(公告)日：2023-08-29

申请号：US16605408

申请日：2018-04-17

Applicant: TEMPEST THERAPEUTICS, INC.

Inventor： Yalda Bravo ,  Jason David Burch ,  Austin Chih-Yu Chen ,  Joe Fred Nagamizo

IPC: A61K31/437 ,  A61K31/404 ,  A61K31/41 ,  A61K31/416 ,  A61K31/4184 ,  A61K39/395 ,  C07D209/08 ,  C07D231/56 ,  C07D235/06 ,  C07D403/12 ,  C07D413/10 ,  C07D471/04 ,  A61P35/00 ,  C07D209/18 ,  C07D235/08 ,  C07K16/28

CPC classification number: A61K31/437 ,  A61K31/404 ,  A61K31/41 ,  A61K31/416 ,  A61K31/4184 ,  A61K39/3955 ,  A61P35/00 ,  C07D209/08 ,  C07D209/18 ,  C07D231/56 ,  C07D235/06 ,  C07D235/08 ,  C07D403/12 ,  C07D413/10 ,  C07D471/04 ,  C07K16/2818 ,  C07K16/2827

Abstract: The present disclosure is directed to novel compounds of Formula I and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g., controlling, alleviating, or slowing the progression of) of cancer, including glioblastoma, bone cancer, head and neck cancer, melanoma, basal cell carcinoma, squamous cell carcinoma, adenocarcinoma, oral cancer, esophageal cancer, gastric cancer, intestinal cancer, colon cancer, bladder cancer, hepatocellular carcinoma, renal cell carcinoma, pancreatic cancer, ovarian cancer, cervical cancer, lung cancer, breast cancer, and prostate cancer. The compounds of the disclosure are selective antagonists of the EP4 receptor and useful treatment of various diseases that may be ameliorated with blockade of PGE2-mediated signaling.

公开(公告)号：US11638704B2

公开(公告)日：2023-05-02

申请号：US17354010

申请日：2021-06-22

Applicant: Tempest Therapeutics, Inc.

Inventor： Yalda Bravo ,  Jason David Burch ,  Austin Chih-Yu Chen ,  Joe Fred Nagamizo

IPC: A61K31/437 ,  A61K31/404 ,  A61K31/41 ,  A61K31/416 ,  A61K31/4184 ,  A61K39/395 ,  C07D209/08 ,  C07D231/56 ,  C07D235/06 ,  C07D403/12 ,  C07D413/10 ,  C07D471/04 ,  A61P35/00 ,  C07D209/18 ,  C07D235/08 ,  C07K16/28

Abstract: The present disclosure is directed to novel compounds of Formula I and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g. controlling, alleviating, or slowing the progression of) of cancer, including glioblastoma, bone cancer, head and neck cancer, melanoma, basal cell carcinoma, squamous cell carcinoma, adenocarcinoma, oral cancer, esophageal cancer, gastric cancer, intestinal cancer, colon cancer, bladder cancer, hepatocellular carcinoma, renal cell carcinoma, pancreatic cancer, ovarian cancer, cervical cancer, lung cancer, breast cancer, and prostate cancer. The compounds of the disclosure are selective antagonists of the EP4 receptor and useful treatment of various diseases that may be ameliorated with blockade of PGE2-mediated signaling.

公开(公告)号：US11066405B2

公开(公告)日：2021-07-20

申请号：US16880756

申请日：2020-05-21

Applicant: Tempest Therapeutics, Inc.

Inventor： Yalda Bravo ,  Jason David Burch ,  Austin Chih-Yu Chen ,  Joe Fred Nagamizo

IPC: C07D471/04 ,  C07D209/18 ,  C07D231/56 ,  A61P35/00 ,  C07D235/08 ,  C07K16/28

Abstract: The present disclosure is directed to novel compounds of Formula I and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g., controlling, alleviating, or slowing the progression of) of cancer, including glioblastoma, bone cancer, head and neck cancer, melanoma, basal cell carcinoma, squamous cell carcinoma, adenocarcinoma, oral cancer, esophageal cancer, gastric cancer, intestinal cancer, colon cancer, bladder cancer, hepatocellular carcinoma, renal cell carcinoma, pancreatic cancer, ovarian cancer, cervical cancer, lung cancer, breast cancer, and prostate cancer. The compounds of the disclosure are selective antagonists of the EP4 receptor and useful treatment of various diseases that may be ameliorated with blockade of PGE2-mediated signaling.